Early trial tests new shot for common liver disease
NCT ID NCT07427680
Summary
This early-stage study aims to find out if a new injectable medicine called TGM-312-SC01 is safe and how it behaves in the body. It will first test single doses in healthy adults, then test multiple doses in adults diagnosed with MASH, a serious form of fatty liver disease. The main goal is to understand the safety and basic effects of the drug before larger studies can begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site 1
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.